Skip to content
OpenCapital
Get started

Maravai LifeSciences Holdings, Inc. MRVI SG&A

SG&A at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$2.18B+5.0%
Danaher logo
DanaherDHR
$1.86B+0.1%
Repligen logo
RepligenRGEN
$76.54M+8.2%
ADMA Biologics logo
ADMA BiologicsADMA
$26.74M+11.1%
Revvity logo
RevvityRVTY
$253.88M+1.7%
TEC
Bio-TechneTECH
$109.34M-27.7%

Other financials

Income statement

See full
Revenue$65.8M+40.5%
Gross profit$33.7M+336%
Operating income-$2.2M+95.6%
Net income-$3.7M+87.5%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$165.9M-41.8%
Total debt$270.9M-17.1%
Total equity$211.6M-29.6%
Total assets$713.2M-25.7%

Cash flow

See full
Operating cash flow$8.7M+192%
CapEx$4.4M-1.4%
Free cash flow$4.2M+130%

Valuation

See full
Market cap$849.64M+204%
Enterprise value$954.59M+198%
P/S4.2×+3.0×

Profitability

See full
Gross margin29.3%-8.0pp
Operating margin-82.2%-16.6pp
Net margin-51.1%-9.9pp
FCF margin-25.7%—

Returns & leverage

See full
Return on equity-40.8%-4.0pp
Debt / equity1.3×+0.2×
Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s SG&A?
Maravai LifeSciences Holdings, Inc. (MRVI) reported SG&A of $29.09M in Q1 2026.
How has Maravai LifeSciences Holdings, Inc.'s SG&A changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s SG&A decreased by 26.5% year-over-year, from $39.56M to $29.09M.
What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s SG&A?
Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s SG&A has grown at a 9.7% compound annual growth rate (CAGR), from $100.06M to $145.12M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.